OPNT News and Press, Opiant Pharmaceuticals Inc. From 04/29/22

Update: Opiant Pharmaceuticals (NASDAQ:OPNT) has advised readers to disregard the news release issued via PR Newswire on Thursday about the purported licensing deal to market the company’s opioid overdose therapy OPNT003 in the EU and U.K. “This release contains incorrect inform...

Santa Monica, California-based Opiant Pharmaceuticals (NASDAQ:OPNT) has entered into a licensing deal with U.K.-based rival, Hikma Pharmaceuticals (OTCPK:HKMPF) (OTCPK:HKMPY) for OPNT003, an experimental therapy targeted at Opioid overdose, the companies announced on Friday. Per the terms of ...

Nasal namalfene, a drug under development from Opiant Pharmaceuticals (NASDAQ:OPNT) for opioid overdose, met its primary endpoint of non-inferiority to nasal naltrexone in a pharmacodynamic study. Topline results showed that namalfene produced a greater reversal of respiratory depression -- a...

Gainers: SQZ Biotechnologies (SQZ) +20%. Amedisys (AMED) +7%. Thermo Fisher Scientific (TMO) +7%. Vascular Biogenics (VBLT) +5%. Opiant Pharmaceuticals (OPNT) +4%. Losers: Teladoc Health (TDOC) -46%. Align Technology (ALGN) -23%. Aptorum Group (APM) -19...

Opiant Pharmaceuticals (NASDAQ:OPNT) on Wednesday announced what it deemed to be positive results from a pharmacodynamic study of its investigational opioid overdose treatment OPNT003, nasal nalmefene. OPNT stock rockets 21.2% to $23.99 in aftermarket trade. Pharmacodynamics is the study of a...

Study compared OPNT003, nasal nalmefene, with 4 mg nasal naloxone hydrochloride in reversing the respiratory depression produced by remifentanil, a synthetic opioid OPNT003 met the primary endpoint of non-inferiority, which was designed to assess whether nasal nalmefene perf...

Citing up to date short interest data as of Apr. 26, Cantor Fitgerald points out that the oncology-focused biopharmaceutical company Veru (NASDAQ:VERU) had the biggest jump in short interest under its coverage with a ~279% increase. Miami, Florida-based Veru (VERU) added more than 25% of valu...

The following slide deck was published by Opiant Pharmaceuticals, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Opiant Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation

Opiant Pharmaceuticals, Inc. (OPNT) Q4 2021 Earnings Conference Call March 15, 2022 4:30 PM ET Company Participants Ben Atkins - Vice President, Communications and Investor Relations Roger Crystal - President and Chief Executive Officer Matt Ruth - Chief Commercial Officer David O'Toole - Chi...

Opiant Pharmaceuticals press release (NASDAQ:OPNT): Q4 GAAP EPS of $0.11 beats by $0.01. Revenue of $13.8M (+39.1% Y/Y) beats by $0.54M. For further details see: Opiant Pharmaceuticals GAAP EPS of $0.11 beats by $0.01, revenue of $13.8M beats by $0.54M